CVS Pharmacy Inc. and related entities will pay $315 million to resolve federal allegations that the chain filled unlawful controlled-substance prescriptions and then billed Medicare and other federal healthcare programs for many of those fills. The Department of Justice announced the dual settlement on October 13, 2026. It is a compromise of disputed claims, not a liability finding. CVS denies the allegations. The agreements say so expressly.
The money splits across two instruments released with the announcement. A False Claims Act settlement requires $189 million plus interest at 3.63% from September 8, 2026, of which $94.5 million is labeled compensatory restitution. A companion Controlled Substances Act settlement requires $126 million. Together they resolve claims in United States ex rel. Hillary Estright v. CVS Health Corporation, et al., No. 22-cv-00222 (D.R.I.), a qui tam filed in 2019, transferred to Rhode Island, and joined by the United States’ consolidated complaint in intervention on December 13, 2024. Relator share under 31 U.S.C. § 3730(d) is not yet fixed. Criminal liability and certain administrative rights, including program exclusion, are reserved.
What held
The government’s theory, as pleaded and as summarized in the press release, is corresponding-responsibility failure at scale. From October 17, 2013 through December 2, 2025, the United States alleged CVS knowingly filled controlled-substance prescriptions that lacked a legitimate medical purpose, were not valid, or were not issued in the usual course of professional practice—including dangerous and excessive opioid quantities, early fills, “trinity” combinations of an opioid, a benzodiazepine, and a muscle relaxant, and scripts from alleged “pill mill” prescribers. Pharmacists allegedly filled despite clear red flags. Many of those fills were then reimbursed by federal healthcare programs. The complaint also alleged that corporate performance metrics, incentive compensation, and staffing policies prioritized throughput over safety, and that policies blocked pharmacists from warning one another about certain problematic prescribers. Those are allegations. There has been no determination of liability.
What operators should read as binding is the forward-looking paper. Exhibit 1 to the CSA settlement is a DEA Memorandum of Agreement for Injunctive Terms. Implementation is 30 days after full execution. The term runs from that date until August 15, 2032. It covers CVS Pharmacy retail stores registered with DEA that fill designated controlled substances (oxycodone, hydrocodone, hydromorphone, tramadol, oxymorphone, morphine, methadone, fentanyl, and alprazolam). Caremark specialty and mail-order pharmacies are carved out. The MOA requires a Controlled Substance Dispensing Oversight Program, annual compliance certifications to DEA, quarterly reports of blocked prescribers, annual training that pharmacists will not be penalized for refusing fills, a patient-note field visible across stores, a Prescriber Review Process that can hard-block scripts system-wide, annual proactive store reviews and site visits, a public/employee hotline, and annual—not merely biennial—controlled-substance inventories. DEA gets notice-and-cure before MOA enforcement; released Covered Conduct claims stay released.
Who has leverage
DOJ and DEA leave with cash, a six-year-plus monitoring architecture, and a published checklist other chains will be measured against in the next qui tam or diversion case. Relator Hillary Estright keeps a live fee fight and an unresolved share. CVS keeps a denial and a dismissal with prejudice once both payments clear, but lives under MOA governance, data sharing at CVS-MOA@dea.gov, and the risk that unresolved Potential Violations after cure can still draw separate enforcement. Individual pharmacists’ DEA registrations at non-CVS pharmacies remain outside the release. Competitors and PBMs get a free look at which red-flag and blocking protocols a national retailer just agreed to run in writing.
What changes Monday
If you run retail pharmacy—or supervise the people who do—map your red-flag resolution and documentation rules against the MOA’s validation section. Confirm pharmacists can refuse fills without compensation pressure tied to controlled-substance revenue. Stand up or stress-test a cross-store patient note, a prescriber-block that actually stops the next fill, and a hotline that reaches compliance, not only HR. Inventory cadence for controlled substances should be annual if you are still on the biennial default. Qui tam risk is not abstract: this file started with a former employee. Performance metrics that silence peer warnings about bad prescribers are now Exhibit A in a $315 million resolution. Pay the check if you are CVS. Copy the monitoring table if you are everyone else.
Sources: DOJ press release (Oct. 13, 2026); FCA Settlement Agreement; CSA Settlement Agreement and DEA MOA Exhibit 1; United States ex rel. Hillary Estright v. CVS Health Corporation, et al., No. 22-cv-00222 (D.R.I.).